Updated: GSK taps Chinese partner to ramp up Shingrix sales in $3.05B deal, with option to expand to RSV
GSK is tapping a heavyweight partner to co-promote its blockbuster shingles vaccine Shingrix in China — and locking in £2.5 billion ($3.05 billion) over the next three years.
Its new partner, Chongqing Zhifei Biological Products, is the largest Chinese vaccine company by revenue, GSK noted. While the pharma giant previously had access to around 9,500 points of vaccination, Zhifei’s service network covers 30,000, according to a GSK spokesperson, marking a significant ramp-up.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
